Science News
from research organizations

Roflumilast improves lung function after 6 months compared with placebo

Date:
October 22, 2012
Source:
American College of Chest Physicians
Summary:
Roflumilast was associated with significant improvements in lung function in patients with moderate and severe chronic obstructive pulmonary disease after six months of treatment compared with placebo.
FULL STORY

Roflumilast was associated with significant improvements in lung function in patients with moderate and severe chronic obstructive pulmonary disease (COPD) after 6 months of treatment compared with placebo. Roflumilast is approved to reduce the risk of exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.

To examine the drug's impact on lung function, researchers from multiple institutions, including Baylor College of Medicine; Takeda Pharmaceuticals International GmbH; and Forest Research Institute, randomized 4,746 subjects to roflumilast (pooled intent-to-treat [ITT], n= 2511; moderate COPD, n=1184; severe COPD, n=1217) or placebo (pooled ITT, n=2235; moderate COPD, n=1098; severe COPD, n=1062). Baseline demographics were similar between treatment groups.

At 6 months, roflumilast increased pre- and postbronchodilator FEV1 by 66 mL and 67 mL, respectively, compared with placebo. Roflumilast, compared with placebo, also increased pre- and postbronchodilator FEV1 in subjects with moderate and severe COPD.

This study was presented during CHEST 2012, the annual meeting of the American College of Chest Physicians, held October 20 -- 25, in Atlanta, Georgia.


Story Source:

The above post is reprinted from materials provided by American College of Chest Physicians. Note: Materials may be edited for content and length.


Cite This Page:

American College of Chest Physicians. "Roflumilast improves lung function after 6 months compared with placebo." ScienceDaily. ScienceDaily, 22 October 2012. <www.sciencedaily.com/releases/2012/10/121022080928.htm>.
American College of Chest Physicians. (2012, October 22). Roflumilast improves lung function after 6 months compared with placebo. ScienceDaily. Retrieved May 2, 2016 from www.sciencedaily.com/releases/2012/10/121022080928.htm
American College of Chest Physicians. "Roflumilast improves lung function after 6 months compared with placebo." ScienceDaily. www.sciencedaily.com/releases/2012/10/121022080928.htm (accessed May 2, 2016).